NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Prostate
Prostate · 333,830 new · 36,320 deaths (ACS 2026) · mortality 18.9 per 100k · 5-yr RS 98.2% (SEER)
Mortality 18.9 per 100k (SEER / ACS common-sites). Never an artboard percent.
Birth-to-death 12.9% (1 in 8) among males (ACS Table 6).
3,700,086 men living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 68 · at death 79 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence men 123.2 per 100k · mortality men 18.9 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among men aged 65–74. Deaths highest among men aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases rising 2.7% each year (2014–2023). Death rates falling 0.8% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Non-Hispanic Black men 200.1 per 100k. Highest death rate: Non-Hispanic Black men 36.2 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | 92.6 | — | 15.0 | — |
| Non-Hispanic American Indian/Alaska Native | 86.7 | — | 17.4 | — |
| Non-Hispanic Asian/Pacific Islander | 66.6 | — | 8.7 | — |
| Non-Hispanic Black | 200.1 | — | 36.2 | — |
| Non-Hispanic White | 122.2 | — | 18.1 | — |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
USPSTF 2018 C · Men 55–69 (D at ≥70) · PSA if elected
Encoded on the published track as an eligibility table — not a personal recommendation. USPSTF-prostate-2018
ACS early-detection pointer
ACS cited · Men considering PSA testing · ACS: informed decision starting at 50 (45 if African American or a father/brother with prostate cancer before 65). This demo encodes USPSTF 2018 Grade C at 55–69. Not equivalent.
Cited ACS statement only. Do not claim USPSTF / NCCN equivalence. ACS-early-detection
AUA screening pointer
AUA 2025 · People considering PSA screening · AUA (2025 amendment): shared decision-making; may offer a baseline PSA at 45–50; offer regular screening every 2–4 years at 50–69; start 40–45 if increased risk. This demo encodes USPSTF 2018 Grade C at 55–69. Not equivalent.
Cited specialty / payer statement only. Do not claim USPSTF / NCCN equivalence. AUA-prostate
Surveillance pointer
AUA-prostate cited · empty on purpose · AUA publishes early-detection guidance. Active-surveillance calendars and PSA kinetics are not encoded. No unpublished interval and no invented month table.
Named public source only. Not a personal follow-up calendar. AUA-prostate
Surveillance pointer
ACS-prostate-follow 2023 · cited only · ACS living-as-a-survivor page names typical PSA tests after treatment, with DRE if the prostate has not been removed. ACS names typical cadences; those months are not encoded. Complementary to the empty-on-purpose AUA active-surveillance pointer. Not a PSA-kinetics engine.
Named public source only. Not a personal follow-up calendar. ACS-prostate-follow
Surveillance pointer
ACS-psa-after 2023 · cited only · ACS PSA-after-treatment page names PSA as a monitoring tool after surgery or radiation, including doubling time, a named 2 ng/mL rise after radiation, and PSA bounce. Those thresholds are not encoded. Complementary to the empty-on-purpose first prostate pointer and the ACS living-as row. Not a PSA-kinetics engine.
Named public source only. Not a personal follow-up calendar. ACS-psa-after
Surveillance pointer
ACS-prostate-follow 2023 · cited only · ACS living-as-a-survivor page says most experts do not recommend additional testing to look for second cancers in men who have had prostate cancer. Complementary to the empty-on-purpose first pointer, the ACS living-as row, and the PSA-after-treatment row. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-prostate-follow
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names osteoporosis after hormone-affecting treatment and heart problems after ADT, plus low testosterone after pelvic radiation or orchiectomy. Those names are not encoded. Complementary to the empty-on-purpose first pointer and the ACS living-as / PSA-after rows. Not a DXA-interval, testosterone, or PSA-kinetics engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page, developed with ASCO review, names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Echoes are named after cardiotoxic chemo. Those plans and tests are not encoded. Complementary to the prostate printout. Not a PSA-kinetics or testosterone engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
AUA-prostate cited · empty on purpose · ADT and prostate-radiation late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. AUA-prostate
Toxicity pointer
ACS-prostate-follow 2023 · empty on purpose · ACS living-as-a-survivor page names treatment side effects. Those late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-prostate-follow
Toxicity pointer
ACS-psa-after 2023 · empty on purpose · ACS PSA-after-treatment page is a monitoring note, not a late-effect engine. Those PSA thresholds are not encoded. Complementary to the empty-on-purpose first prostate toxicity pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-psa-after
Toxicity pointer
ACS-prostate-follow 2023 · empty on purpose · ACS living-as-a-survivor page names later cancers after prostate-cancer treatment. Those second-cancer risks are not encoded. Complementary to the empty-on-purpose first pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-prostate-follow
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later heart problems after ADT, osteoporosis, and low testosterone after pelvic treatment. Those late effects are not encoded. Complementary to the empty-on-purpose first pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after prostate treatment. Echoes are named after cardiotoxic chemo. Those named tests are not encoded. First-row prostate toxicity stays empty on purpose. Not a PSA-kinetics or testosterone engine. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — Prostate
Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, and nausea. Late: radiation proctitis and cystitis, incontinence, fertility and sexual side effects, low testosterone, osteoporosis, heart problems after ADT, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: lingering rectal or bladder symptoms after 3 to 6 months; echoes after cardiotoxic chemo; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. First-row prostate toxicity stays empty on purpose. Not a PSA-kinetics or testosterone engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
ACS follow-up tests named here
Echoes after cardiotoxic chemo
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS pelvis / prostate names only. Complementary ACS long-term page is named, not encoded. First-row prostate toxicity stays empty on purpose. No invented trial percent.
Open Prostate printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-prostate · approximation · evaluateProstate · USPSTF-2018+RR
SEER 5-year relative survival by stage
Localized 100% · Regional 100% · Distant 34.1% · All 98.2%
Localized/regional approach 100% in SEER summaries.
Percent of cases by stage (SEER Stat Facts)
Localized 69% · Regional 14% · Distant 9% · Unknown 8%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage.
lifetime
Prostate birth-to-death (males)
12.9% (1 in 8)
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
—USPSTF prostate screening discussion is framed for men
screening
USPSTF 2018 shared decision 55–69 (Grade C)
USPSTF prostate screening discussion is framed for men
out of domain
surveillance
No encoded active-surveillance calendar
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
out of domain
toxicity
No prostate-treatment toxicity engine
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
out of domain
Noah · Plan — skin cancer
12.90 educational %shared decision 55–69 (USPSTF 2018 Grade C) · RR ×1.00
screening
USPSTF 2018 shared decision 55–69 (Grade C)
Shared-decision PSA conversation — not an automatic order
on this plan
surveillance
No encoded active-surveillance calendar
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
empty on purpose
toxicity
No prostate-treatment toxicity engine
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
empty on purpose
Walter · S1 prostate
23.22 educational %shared decision 55–69 (USPSTF 2018 Grade C) · RR ×1.80
screening
USPSTF 2018 shared decision 55–69 (Grade C)
Shared-decision PSA conversation — not an automatic order
on this plan
surveillance
No encoded active-surveillance calendar
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
empty on purpose
toxicity
No prostate-treatment toxicity engine
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
empty on purpose
Priya · average-risk
—USPSTF prostate screening discussion is framed for men
screening
USPSTF 2018 shared decision 55–69 (Grade C)
USPSTF prostate screening discussion is framed for men
out of domain
surveillance
No encoded active-surveillance calendar
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
out of domain
toxicity
No prostate-treatment toxicity engine
Empty on purpose — no encoded active-surveillance or ADT toxicity engine
out of domain
Not PCPTRC. No PSA value. The composed 15-screen prostate figure stays on the artboard; this row uses ACS Table 6 12.9% × RR.